Dare Bioscience (DARE) Stock Price, News & Analysis

Company Overview

Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery. The company’s research strategy emphasizes platform versatility, enabling potential applications in areas such as mucosal immunization and topical therapies for vaginal health. Dare collaborates with academic institutions and strategic partners to leverage emerging technologies and expand its product opportunities within the women’s health market.

Headquartered in San Diego, California, Dare Bioscience operates in the United States and is listed on the Nasdaq Global Market under the ticker symbol DARE. The company is led by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial execution. Dare’s leadership is committed to advancing its clinical programs and delivering new options for women’s reproductive care.

Key Stats

• Today's Range: $3.13 to $3.78
• 50-Day Range: $1.30 to $3.27
• 52-Week Range: $1.27 to $9.19
• Volume: 2.37 million shs
• Average Volume: 1.12 million shs
• Market Capitalization: $47.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

Dare Bioscience Stock Analysis - MarketRank™

Dare Bioscience scored higher than 41% of companies evaluated by MarketBeat, and ranked 597th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Dare Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Dare Bioscience has a consensus price target of $10.00, representing about 205.8% upside from its current price of $3.27.

Amount of Analyst Coverage

Dare Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Dare Bioscience is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dare Bioscience is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dare Bioscience has a P/B Ratio of 16.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.23% of the float of Dare Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Dare Bioscience has a short interest ratio ("days to cover") of 2.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dare Bioscience has recently decreased by 19.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dare Bioscience does not currently pay a dividend.

Dividend Growth

Dare Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

9 people have searched for DARE on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.

MarketBeat Follows

4 people have added Dare Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dare Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.80% of the stock of Dare Bioscience is held by insiders.

Percentage Held by Institutions

6.70% of the stock of Dare Bioscience is held by institutions.

DARE Stock Analysis - Frequently Asked Questions

How have DARE shares performed this year?

Dare Bioscience's stock was trading at $1.93 at the start of the year. Since then, DARE shares have increased by 69.4% and is now trading at $3.27.

How were Dare Bioscience's earnings last quarter?

Dare Bioscience, Inc. (NASDAQ:DARE) announced its earnings results on Thursday, March, 26th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.42. The biotechnology company had revenue of $1.02 million for the quarter, compared to analyst estimates of $0.75 million.
Read the conference call transcript.

When did Dare Bioscience's stock split?

Dare Bioscience shares reverse split on Monday, July 1st 2024.The 1-12 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

When did Dare Bioscience IPO?

Dare Bioscience (DARE) raised $102 million in an IPO on Thursday, April 10th 2014. The company issued 8,500,000 shares at $11.00-$13.00 per share.

How do I buy shares of Dare Bioscience?

Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dare Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dare Bioscience investors own include FuelCell Energy (FCEL), Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 3/26/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DARE
• CIK: 1401914
• Web: www.darebioscience.com
• Phone: (858) 926-7655
• Fax: 617-494-1544
• Employees: 30
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Dare Bioscience: $10.00
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +205.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.40 million
• Net Margins: N/A
• Pretax Margin: -1,300.87%
• Return on Equity: N/A
• Return on Assets: -56.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.14
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: $1.03 million
• Price / Sales: 46.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 16.35

Miscellaneous

• Outstanding Shares: 14,560,000
• Free Float: 13,861,000
• Market Cap: $47.61 million
• Optionable: Not Optionable
• Beta: 1.09